Caspofungin Market Share 2022-2030 Johnson Controls, Exide Technologies, East Penn Manufacturing

Caspofungin Market – Snapshot

Caspofungin is an antifungal drug that works by inhibiting the enzyme (1→3)-β-D-glucan synthase, thereby disturbing the integrity of the fungal cell wall. Caspofungin acetate was first approved by the U.S. Food and Drug Administration (FDA) on January 26, 2001, then by the European Medicine Agency (EMA) on October 24, 2001, and approved by Pharmaceuticals and Medicals Devices Agency of Japan (PMDA) on January 18, 2012. It was developed and marketed as Cancidas by Merck Sharp & Dohme (U.S.).

Get the sample copy of report@ https://qyresearchmedical.com/sample/111952

The global caspofungin market was valued at US$ 484.60 Mn in 2018 and is anticipated to reach US$ 496.20 Mn by 2027, expanding at a CAGR of 0.18% from 2019 to 2027. Rise in prevalence of candidiasis, increase in usage of echinocandins, surge in disposable income in the emerging countries, and rise in awareness among people about preventive measures of various microbial diseases are factors projected to propel the global market during the forecast period.

caspofungin market

The incidence and prevalence of invasive candidiasis are rising significantly across the world, affecting millions of people. Increase in incidence of candidaemia in ICUs has been reported in several parts of the world. According to the Extended Prevalence in Intensive Care (EPIC) II point prevalence study, Candida spp. is the third most recurrent cause of infection in ICUs across the globe, accounting for 17% of all ICU infections in culture-positive infected patients. Moreover, according to the U.S. Department of Health & Human Services, invasive candidiasis is one of the common health care-associated infections. Around 46,000 cases of invasive candidiasis occur each year in the U.S. Candida species are ranked fifth among hospital-acquired pathogens and fourth among nosocomial blood stream infection pathogens. Increase in incidence of invasive candidiasis is expected to be a major factor likely to boost the global caspofungin market during the forecast period.

The global caspofungin market has been segmented based on indication, distribution channel, and region. In terms of indication, the candidiasis segment is projected to account for major share of the global market during the forecast period. Caspofungin has been approved as first line of treatment of patients suffering from invasive candidiasis and who are resistant to other antifungal agents. It has been also approved as first line of treatment for different forms of candidiasis such as esophageal candidiasis, intra-abdominal abscesses, peritonitis, and pleural space infections. The preferred use of caspofungin over other antifungals in certain diseases is likely to propel the market during the forecast period.

In terms of region, the global caspofungin market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Developed regions such as North America and Europe accounted for leading shares of the global market in 2018. Large patient population and presence of major pharmaceutical companies can be attributed to high share of these regions. Moreover, rise in prevalence of fungal diseases and increase in the geriatric population drive the caspofungin market in North America and Europe. The market in Asia Pacific is projected to expand at a high CAGR owing to rapidly improving health care facilities in countries such as India, China, South Korea, and Malaysia. China dominated the caspofungin market in Asia Pacific in 2018. The market in India is anticipated to expand at a significant CAGR during the forecast period. Furthermore, increase in investment by leading players and introduction of generics by other players are expected to fuel the growth of the market in the region. The market in Latin America and Middle East & Africa is likely to expand at a steady pace during the forecast period.

View full report@ https://qyresearchmedical.com/report/caspofungin-market-indication-candidiasis-thrush-distribution-channel-hospital-pharmacies-retail-pharmacies-online-pharmacies-global-industry-analysis-size-share-growth-trends-and-forecast-2019-2030/111952

Prominent players operating in the global caspofungin market include Teva Pharmaceutical Industries Ltd., Mylan N.V , Merck & Co., Inc., Fresenius SE & Co. KGaA , Gland Pharma Limited, and Xellia Pharmaceuticals.

Caspofungin Market – Snapshot

Caspofungin is a lipopeptide antifungal drug from Merck & Co., Inc. discovered by James Balkovec, Regina Black and Frances A. Bouffard. It is a member of a new class of antifungals termed the echinocandins. It works by inhibiting the enzyme glucan synthase and thereby disturbing the integrity of the fungal cell wall. Caspofungin was the first inhibitor of fungal glucan synthesis to be approved by the United States Food and Drug Administration.

Caspofungin is administered intravenously. It has been effective in treating fungal infections caused by Aspergillus and Candida species. It is a member of the echinocandin family, a new class of antifungal agents with broad spectrum of activity against all Candida species. In comparison to treatment with either fluconazole or Amphotericin B, all three drugs in this class have been demonstrated to be highly effective or superior in well-defined clinical settings including invasive Candida infections, Candida oesophagitis and candidaemia. Caspofungin has been shown in animal studies to have embroyotoxic properties, and therefore has been assigned to class C. It should only be given to pregnant women if the benefit to the mother clearly outweighs the potential risk to her fetus.

Its currently approved therapeutic indications by both organisations include the empirical therapy of presumed fungal infections in febrile, neutropenic adult patients and for salvage therapy in patients treatment of invasive aspergillosis in adult patients whose disease is refractory to, or who are intolerant of, other antifungal agents (i.e., conventional or lipid formulations of amphotericin B and/or itraconazole). Additionally, the FDA approval includes indication for the treatment of candidemia and some specific Candida infections (intra-abdominal abscesses, peritonitis, pleural cavity infections, and esophagitis) and the EMEA approval includes indication for the treatment of general invasive candidiasis in adult patients.

Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/111952/2900

Slowly metabolized by peptide hydrolysis and N-acetylation in liver. Therefore, in case of liver impairment the dose needs to be reduced. Caspofungin also undergoes spontaneous chemical degradation to an open-ring peptide compound, L-747969. Additional metabolism involves hydrolysis into constitutive amino acids and their derivatives, including dihydroxyhomotyrosine and N-acetyl-dihydroxyhomotyrosine.

The global caspofungin market has been segmented as follows:

Indication

  • Candidiasis
  • Thrush

Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Region

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Rest of Europe
  • Asia Pacific
  • Australia & New Zealand
  • Japan
  • China
  • India
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East & Africa
  • GCC Countries
  • South Africa
  • Israel
  • Rest of Middle East & Africa

TABLE OF CONTENT

Section 1 Preface
1.1 Report Scope and Market Segmentation
1.2 Research Highlights

Section 2 Assumptions and Research Methodology
2.1 Assumptions
2.2 Research Methodology

Section 3 Executive Summary
3.1 Global Caspofungin Market Snapshot
3.2 Key Industry Developments

Section 4 Market Overview
4.1 Caspofungin Market Taxonomy
4.2 Caspofungin Drug Introduction
4.3 Global Caspofungin Market Size (US$ Mn) Forecast, 2017–2027
4.4 Global Caspofungin Market: Market Outlook
4.5 Rise in incidence of invasive candidiasis across the globe
4.5.1.Rise in geriatric population
4.5.2.Advantages of echinocandins over other antifungal
4.5.3.Restraints
4.5.3.1 Availability of Generic Drugs
4.5.3.2 Emergence of resistant species
4.5.4 Opportunities
4.5.4.1 Echinocandins, as first line of therapy in candidiasis
4.5.4.2 Expansion of Research and Development in Emerging Markets

Section 5 Key Insights
5.1 Clinical Trial Pipeline Analysis
5.2 Disease Prevalence & Incidence Rate globally with key countries
5.3 Supply Chain Analysis
5.4 Pricing Analysis by Manufacturers

Section 6 Global Caspofungin Market Analysis, by Indication
6.1 Key Findings
6.2 Introduction
6.3 Market Value Share Analysis, by Indication
6.4 Market Value Forecast, by Indication, 2017–2027
6.5 Market Analysis, by Indication, 2017–2027
6.5.1 Candidiasis
6.5.2 Thrush
6.6 Market Attractiveness, by Indication

Section 7 Global Caspofungin Market Analysis, by Distribution Channel
7.1 Key Findings
7.2 Introduction
7.3 Market Value Share Analysis, by Distribution Channel
7.5.1. Hospital Pharmacies
7.5.2 Retail Pharmacies
7.5.3 Online Pharmacies
7.6 Market Attractiveness, by Distribution Channel

Section 8 Global Caspofungin Market Analysis, by Region
8.1 Market Value Share Analysis, by Region
8.2 Market Forecast, by Region
8.3 Global Caspofungin Market Attractiveness Analysis, by Region

Section 9 North America Caspofungin Market Analysis
9.1 Market Overview
9.2 Market Value Share Analysis, by Indication
9.3 Caspofungin Market Forecast, by Indication
9.4 Market Value Share Analysis, by Distribution Channel
9.5 Caspofungin Market Forecast, by Distribution Channel
9.6 U.S.
9.6.1 Canada
9.7 Market Attractiveness Analysis
9.7.1 By Country
9.7.2 By Indication
9.7.3 By Distribution Channel

Section 10 Europe Caspofungin Market Analysis

……..

Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/111952/2900

You can place an order or ask any questions, please feel free to contact sales@qyresearchmedical.com | +1 9197 992 333

About Us

QYResearch Medical, focuses on custom research, management consulting, IPO consulting, industry chain research, and data base & seminar services. The company owns large basic databases (such as National Bureau of Statistics Database, Customs Import and Export Database, Industry Association Database, etc.), expert resources (including industry experts who own more than 10 years experiences on marketing or R&D in industries of healthcare services, medical technology & devices, etc.), professional survey team (the team members obtained more than 3 years market survey experience and more than 2 years deep expert interview experience), and excellent data analysis team (SPSS statistics and PPT graphics process team).

QYResearch Medical has more than 4000 global well-known customers, covering more than 30 industries including pharmaceuticals, medical technology & devices, healthcare services etc. Company services cover one-stop solution as Data-Analysis-Suggestion-Consulting Implementation. Research regions cover China, US, EU, Asia, Middle East and Africa, South America, Australia, and other regions in the world.

For Latest Update Follow Us:

https://www.linkedin.com/company/qyresearch-medical/

https://www.facebook.com/QYResearch-Medical-108186514228917/

https://twitter.com/qyresearchmedi